Chronic mucosal inflammation is the hallmark of important and common airway diseases, such as allergic rhinitis and asthma. Lipoxin A 4 (LXA 4 ) is an endogenous pro-resolving mediator for mucosal inflammation that decreases allergic and asthmatic responses. Lipoxin B 4 (LXB 4 ) is a structurally distinct member of the lipoxin family that signals in a manner distinct from LXA 4 . LXB 4 is generated by mucosal tissues, but its actions in allergic inflammation are unknown. Here, we used murine models of allergic rhinitis and asthma to investigate LXB 4 's activity in mucosal inflammation. In the upper airway, LXB 4 significantly decreased nasal mucosal leukocytes and degranulation of mast cells and eosinophils. In the lower airway, LXB 4 significantly decreased airway inflammation, mucus metaplasia and hyper-responsiveness. Inhibition of mast cell degranulation in vivo by LXB 4 was more potent than dexamethasone, and these agents displayed unique profiles for cytokine regulation; however, their overall anti-inflammatory actions were comparable. LXB 4 decreased eotaxin-dependent eosinophil chemotaxis, IgE-mediated mast cell degranulation and expression of type 2 cytokine receptors. Together, these findings indicate that LXB 4 carries cell type selective and mucosal protective actions that broaden the lipoxin family's therapeutic potential for upper and lower airway catabasis.
INTRODUCTION
Allergic airway diseases, such as rhinitis and asthma, are common and adversely impact patients function and quality of life [1] [2] . Allergic rhinitis (AR) and atopic asthma can present with chronic mucosal inflammatory processes, and have been referred to as a "united airways" disease [3] [4] . Despite distinct clinical manifestations, these diseases have immunological similarities. For example, eosinophil tissue infiltration and IgE-mediated mast cell (MC) activation through FcεRI bound allergen are major factors in the pathogenesis of AR and atopic asthma 5 . Current treatments for AR and asthma principally target symptom relief and anti-inflammation with glucocorticosteroids (GC). Since GC are associated with heterogeneous therapeutic responses and can have serious side effects, there is still a need for new treatment strategies to control AR and asthma. Importantly, no curative therapy is available to resolve allergic airway inflammation.
Recently, research focused on the physiological termination of inflammatory responses has led to the identification of specialized mediators involved in the natural resolution of inflammation in health, including lipoxins (i.e., lipoxin A 4 (LXA 4 ), lipoxin B 4 (LXB 4 )) 6 . These specialized pro-resolving mediators are lipoxygenase-derived eicosanoids formed from arachidonic acid by transcellular metabolism during cell-cell interactions (reviewed in 6 ). Lipoxins are generated by the upper respiratory tract, including by nasal polyps 7 , and are present in nasal lavage fluids from aspirin-challenged patients with aspirin-exacerbated respiratory disease 8 . Lipoxins are also present in the lower airways in broncho-alveolar lavage fluid (BALF) from patients with asthma 9 . Of note, severe asthma is associated with decreased LXA 4 generation 9 . Administration of a stable analog of LXA 4 blocks allergic airway inflammation, mucus metaplasia and hyper-reactivity to methacholine 10 . LXA 4 is a potent inhibitor of granulocyte recruitment and activation, including eosinophils 10 . LXB 4 is a structurally distinct product of arachidonic acid metabolism. LXB 4 regulates neutrophil activation 11 ; however, its actions in allergic inflammation and on the functional responses of mucosal effector cells (i.e. MC and eosinophils), has yet to be established. Here we provide the first evidence that LXB 4 mediates anti-inflammatory and pro-resolving actions for allergic airway responses in murine models of upper and lower airway mucosal inflammation.
RESULTS

LXB 4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa
Mice (BALB/c) were systemically sensitized with OVA/Alum and then challenged with OVA intranasally to target the allergic responses to the nasal mucosa ( Figure 1a , see Methods). Twenty four hours after the last nasal allergen challenge, mice were given LXB 4 (as validated in Supplementary Figure S1 ) (100 ng, i.v), dexamethasone (100 ng) or vehicle control for 3 consecutive days (protocol day 28, 29, 30) (Figure 1a ). Mice were sacrificed 24 hours later (protocol day 31). Histopathological assessment of the nasal cavity in mice exposed to vehicle, revealed mucosal allergic inflammation with mucin secretion and leukocyte infiltration (Figure 1b) . Relative to vehicle, LXB 4 reduced inflammatory infiltrates and mucin secretion in the lumen (Figure 1c ). Equivalent amounts of dexamethasone also decreased the mucosal inflammation, but to a lesser degree than LXB 4 (Figure 1d ). BALF that was collected from these mice at the time of nasal tissue excision did not reveal significant increases in eosinophils or other leukocytes (data not shown).
LXB 4 has pro-resolving actions on select nasal mucosa cell populations
Leukocyte infiltration and total nasal mucosal cell numbers were significantly decreased by LXB 4 compared to vehicle (Figure 2a) . Differential cell count performed on Wright-Giemsa stained cytospins of nasal mucosa cells indicated a significant decrease in eosinophils numbers with LXB 4 and dexamethasone (Figure 2b ). The numbers of MC still containing granules significantly increased with LXB 4 while dexamethasone gave no significant changes from vehicle ( Figure 2c ).
Mast cell and eosinophil degranulation is decreased by LXB 4
Examination of the cytospins following Wright-Giemsa staining revealed striking evidence of changes in leukocyte granule contents (Figure 3 ). Mice (BALB/c) exposed to vehicle had highly degranulated eosinophils and MC with evidence for released MC granules ( Figure  3a) . In sharp contrast, nasal mucosal MC from LXB 4 treated mice were larger and retained most of their granule contents, indicative of a less activated state (Figure 3b ). Eosinophils also appeared less degranulated (Figure 3b ). Nasal mucosal MC following dexamethasone treatment showed cellular changes consistent with partial activation and degranulation with cells generally smaller in size than with LXB 4 ( Figure 3c ). Next, the apparent decrease in eosinophils number and degranulation was validated by flow cytometry analysis where Siglec-F + cells (Supplementary Figure S2a) and CD107a + cells (Supplementary Figure S2b) were significantly decreased by LXB 4 Figure S2a ), but had no significant effect on cell degranulation (CD107a + , p=0.531, Supplementary Figure S2b ).
LXB 4 decreases serum OVA-specific IgE levels and select cytokines/chemokines
Serum titers of OVA-specific IgE (BALB/c mice) were significantly decreased with LXB 4 (0.57±0.10 pg/ml, p<0.01) and dexamethasone (0.56±0.08 pg/ml, p<0.01) relative to vehicle (1.54±0.29 pg/ml) (Figure 4a ). Additionally, LXB 4 significantly decreased serum levels of several mediators associated with IgE production and allergic responses (Figure 4b Figure 4f ) and IL-12 ( Figure 4h ). Monocyte chemoattractant protein-1 (MCP-1) was also decreased by LXB 4 , but did not reach statistical significance with this sample size (Figure 4g ; p=0.053). Dexamethasone did not share LXB 4 's broad immunoregulatory actions at this time point, but did decrease serum IL-4, IL-9 and GM-CSF (Figure 4b, 4c, 4e ). Of interest, LXB 4 gave modest increases in keratinocyte chemoattractant (KC) (Figure 4i ; p<0.01) and IL-13 ( Figure 4j , p<0.05) levels. The increased serum KC level was not associated with increased tissue neutrophils in the nasal mucosa. Levels of IL-5 were not significantly influenced by either LXB 4 or dexamethasone (Figure 4k ). Serum levels of IL-17 were also detected and significantly down-regulated by LXB 4 (Figure 4l , p<0.01), but not by dexamethasone (Figure 4l ).
LXB 4 decreases bone marrow-derived MC degranulation and bone marrow-derived eosinophil chemotaxis
To quantitatively determine if LXB 4 carried direct actions for cell functional responses, IgEsensitized bone marrow (BM)-derived mast cells (BMMCs) from naive mice were exposed to LXB 4 and compared to LXA 4 , dexamethasone or vehicle. Cell activation for degranulation was initiated in a non-antigen specific manner with an IgG (Fab)2' antibody as in 12 
LXB 4 and LXA 4 decrease cytokine release from BMMC following IgE-mediated activation
Based on the serum cytokine regulation of AR mice by LXB 4 , the direct actions of lipoxins on BMMC cytokine release was next determined. BMMC were exposed to LXB 4 , LXA 4 or vehicle prior to activation. After 18 hrs, IgE-mediated activation of BMMC led to a significant TNF-α release that was significantly inhibited by LXB 4 
LXB 4 regulates allergic lung inflammation
To determine if the actions of LXB 4 in the lower airways were similar to the upper airways, we first investigated the anti-inflammatory activity of LXB 4 ( Figure 7I .Prevention). OVA sensitized animals (FVB) received LXB 4 (100ng, 1000ng) or vehicle (i.v.) 30 minutes before OVA aerosol challenge on protocol days 14-17 and were then sacrificed 24 hours later on day 18-a time of peak allergic inflammation. LXB 4 led to a significant dosedependent decrease in total BALF cell numbers ( Figure 7I Given these anti-inflammatory actions, LXB 4 's pro-resolving actions in the lower airways were next determined by administration after the allergic airways responses were fully established ( Figure 7II . Treatment). Twenty four hours after the last OVA aerosol challenge, LXB 4 (100ng, i.v.) was given (protocol day 18) and repeated on days 19 and 20. Mice were sacrificed 24 hours later (day 21) during the resolution phase of this model. Relative to vehicle, LXB 4 significantly accelerated the resolution of the allergic lung inflammation with decreased BALF total cell number ( Figure 7II . e) and decreased eosinophils, macrophage and lymphocyte numbers ( Figure 7II . f-h). The resolution interval (R i ) was calculated for BALF total cells (approximately 6 days with vehicle) and LXB 4 shortened the R i by over 30% to ~4 days ( Figure 7II . i).
LXB 4 promotes the resolution of Airway Hyper-responsiveness and lung inflammation
In addition to airway inflammation, airway hyperresponsiveness (AHR) is a clinical hallmark of asthma 1 , therefore the impact of LXB 4 on methacholine-triggered increases in lung resistance was determined. Relative to vehicle, mice (FVB) exposed to 100ng LXB 4 treatment (as in Figure 7II .) had significantly less AHR to methacholine (Figure 8a ). In addition, histological analysis of lung sections from animals not subjected to AHR testing revealed that LXB 4 led to significant reductions in leukocyte infiltration and epithelial cell activation (Figure 8b 
DISCUSSION
Allergic rhinitis and asthma are common allergic conditions with high morbidity. Allergen avoidance is often difficult and impractical and there is no curative therapy for the resultant allergic inflammation. Thus, new therapeutic approaches are needed. To this end, LXB 4 (~5µg/kg) displayed pro-resolving actions for allergic mucosal inflammation in murine models of AR and asthma. LXB 4 decreased mucosal leukocyte infiltration, OVA-specific IgE, MC and eosinophils degranulation, mucus metaplasia and AHR to methacholine. LXB 4 mediated direct actions on pivotal cellular effectors for allergy, namely MC and eosinophils (as shown on cell functional responses in vitro), as well as indirect actions on these cells (regulation of levels of inflammatory mediators). Distinct from their important role during the induction of allergic airway responses, the levels of type 2 cytokines during resolution and their response to LXB 4 varied. In resolving upper and lower airways, LXB 4 potently decreased serum IL-4 and IgE levels. Because significant changes were not present in IL-5 levels, LXB 4 regulation of eosinophils function appears to have resulted from a direct action on these cells as well as from the reduced levels of GM-CSF. Surprisingly, LXB 4 increased serum IL-13 as the upper airways resolved. In contrast, BALF IL-13 was decreased by LXB 4 , suggesting local and distinct regulatory mechanisms. Although IL-13 can initiate allergic inflammation, it can also play a role in limiting inflammation. Of note, IL-13 has the capacity to induce the expression of 15-lipoxygenase, which catalyzes the formation of both LXB 4 and LXA 4 6 .
IL-4 plays important roles in isotype switching and IgE production [17] [18] , and LXB 4 inhibited both IL-4 and serum IgE levels. Given the differential actions on IL-13 levels, expression of its receptors was determined. Lung expression of IL-4R, IL-13Rα1 and IL-13Rα2 were down regulated during resolution and further decreased by LXB 4 . IL-4R deficient mice display weak Th2 responses 19 . IL-13Rα1 deficiency has an established role in allergic airway responses 20 . Thus, LXB 4 regulation of IL-4R and IL-13Rα1 expression would serve to decrease mucus metaplasia and airway hyper-reactivity. No LXB 4 -mediated increases in expression of the IL-13 decoy receptor IL-13Rα2 were apparent. In asthma, regulation of IgE and IL-13 has beneficial actions in some asthmatic patients [21] [22] , so together these findings suggest therapeutic potential for LXB 4 or its stable analogs 23 .
The increase of serum KC with LXB 4 was unexpected and distinct from LXA 4 24 . In addition to its well defined role as a neutrophil chemoattractant, KC can modulate ciliary function of murine sinonasal epithelial cells [25] [26] , suggesting that LXB 4 might enhance mucociliary clearance via this mechanism. In contrast to KC, serum IL-17 levels were low and significantly decreased by LXB 4 . Compared to the GC dexamethasone, LXB 4 's actions were of similar potency for decreasing inflammatory cell activation and more potent for regulating degranulation in vivo. Although consistently decreased by LXB 4 , there was donor-to-donor variability for the magnitude of stimulus-driven BMMC degranulation, suggesting context dependent responses for mast cells and their regulation by LXB 4 . Direct cellular actions for LXB 4 were also identified in vitro for inhibition of BMMC TNF-α production and BM-derived eosinophil chemotaxis. Together, these lines of evidence support potent anti-allergic and pro-resolving actions for LXB 4 on MC and eosinophils that were relevant for both upper and lower airways.
Notably, LXA 4 blocks histamine release from MC during interactions with epithelial cells 27 and decreases neutrophil degranulation of azurophilic granules 28 . In conjunction with LXB 4 's actions here in vitro, the lipoxins (LXA 4 and LXB 4 ) carry MC and granulocyte stabilizing activity. Apart from its direct regulation of MC and eosinophils, LXB 4 blocks Tcell activation, cytokine release 29 and neutrophil chemotaxis 11 . Indirect mechanisms are also likely in the accelerated resolution of allergic lung inflammation, as levels of several inflammatory mediators, including GM-CSF, a pro-survival cytokine for eosinophils, were decreased by LXB 4 . Of interest, LXA 4 has a counter-regulatory effect on GM-CSF signaling in a human eosinophil cell line (EoL-1) and peripheral blood eosinophils 30 . LXA 4 also inhibits human eosinophils recruitment in vitro 31 and murine eosinophils in vivo 10 , and can induce natural killer cells to promote human eosinophils apoptosis in asthma in order to enhance their non-phlogistic clearance from inflamed tissues 32 . Together, these findings highlight several cellular mechanisms for lipoxin regulation of allergic airway inflammation.
LXB 4 and LXA 4 are generated by nasal polyps where a mucosal epithelial 15-lipoxygenase plays an important role in their biosynthesis. LXA 4 is present in nasal secretions 10 and airway samples from human asthmatic patients 9 , 33 . Eosinophilic donors generate LXA 4 preferentially to LXB 4 34 , however, this is cell type specific as human platelet 12-lipoxygenase converts leukotriene A 4 to LXA 4 and LXB 4 in an equimolar ratio 35 , and IL-4 exposed alveolar macrophage 15-lipoxygenase generates LXB 4 preferentially to LXA 4 36 .
The nanogram doses of LXB 4 used here are within physiological concentrations generated during inflammatory responses and were very potent (~5µg/kg) in comparison to a similar dose of dexamethasone. LXA 4 interacts with several receptors, including the G-protein coupled receptor ALX/FPR2. While LXB 4 also displays pharmacological properties of a Gprotein coupled receptor agonist, it binds to a receptor distinct from ALX/FPR2 that has yet to be identified. In conclusion, LXB 4 displayed pro-resolving actions for mucosal allergic responses in the upper and lower airways. LXB 4 is generated in the airway and the present results are the first demonstration of an airway protective effect for LXB 4 or that any specialized pro-resolving mediator is active in the nasal mucosa. With the development of LXB 4 stable analogs and the limited treatment options currently available, these findings suggest a potential new pro-resolving therapeutic strategy for allergic conditions.
Materials & Methods
Materials
Lipoxin A 4 and Lipoxin B 4 were from Cayman Chemical (Ann Arbor, Michigan, USA) and dexamethasone was from MP Biomedicals LLC (Solon-Ohio, USA). The lipoxins were stored at −80°C under a blanket of N 2 and their integrity was monitored by UV-Vis spectrophotometry and HPLC (Supplementary Figure S1 Online).
Allergic upper and lower airway models
The allergic upper airway model was designed to reflect AR and was a modification of a previously published protocol 37 ( Figure 1) . Briefly, BALB/c female mice (Harlan Laboratories), aged 7-8 weeks (20-23gr) were sensitized on day 0 and day 7 by intraperitoneal injection (i.p.) of 200µl chicken ovalbumin (OVA; 1mg/ml) (Amresco, Ohio, USA) and aluminum hydroxide (alum; 50 mg/ml) (Acros Organics, New Jersey, USA) in PBS. Starting on day 14, awake mice were challenged twice a day by intranasal (i.n.) instillation of 20µl OVA (25mg/ml) daily until day 27. For the allergic lower airway model, a previously published protocol with OVA was used to reflect atopic asthma 38 . Briefly, FVB male mice aged 5-7 weeks (Charles River Laboratories) were housed in isolation cages under viral antibody-free conditions. Mice were fed a standard diet (Laboratory Rodent Diet 5001, PMI Nutrition International). Mice were sensitized with i.p. injections of OVA (10µg) and 1mg alum in 0.2ml saline on days 0 and 7. Mice were then challenged on days 14-17 with an aerosol of 6% OVA (25min).
Treatment protocols
Mice were given either intravenous (i.v.) LXB 4 (100ng or 1000ng), vehicle (0.1% ethanol) or dexamethasone (100ng). To determine pro-resolving actions, treatments were given after the completion of allergen challenge at peak allergic airway inflammation time: days 28, 29, 30 in the upper airway model (Figure 1a ) or days 18, 19 and 20 in the lower airway model ( Figure 7II ). Calculation of the resolution interval (R i ) (i.e. time interval for the maximum number of cells to decrease by 50%) was then evaluated as in 39 . To determine antiinflammatory actions, LXB 4 (100ng) or vehicle were given i.v. on protocol days 14, 15, 16 and 17, 30 minutes prior to OVA aerosol challenge ( Figure 7I ). Twenty four hours after the last i.v. treatment, mice were euthanized for the collection of airway and systemic specimens. Mouse experiments were approved by the Animal Ethics committee, The Hebrew University, Jerusalem, Israel, and the Harvard Medical Area IRB, Boston, MA, USA (Protocol #03618).
Nasal tissue preparation of cell suspensions and histopathology
As in 37 , extensive dissection was required to obtain the nasal mucosa cell suspensions (see supplemental methods in the Online Data Supplement). Total viable cell numbers were enumerated by Trypan blue exclusion. Nasal tissue sections were prepared and stained for H&E.
Flow cytometry
Single cell suspensions from nasal mucosa were resuspended in PBS/0.1% bovine serum albumin (BSA) seeded in a 96-well plate at 10 6 cells/ml, blocked with 5% goat serum and stained with Phycoerythrin conjugated anti-CD107a (eBioscience, San Diego, California, USA) and anti-Siglec-F (BD biosciences) for the detection of total degranulation 40 and eosinophils, respectively. For in vitro assessment of BMMC expression of FCεRI, cells were stained with anti-FCεRI (eBioscience, San Diego, California, USA) and cell viability was determined by propidium iodide staining (Sigma Aldrich, Rehovot, Israel). Data were analyzed by a FACSCalibur and CellQuest software (Becton Dickinson, San Jose California, USA).
LXA 4 /LXB 4 activity on mouse bone marrow derived mast cells (BMMC) and eosinophils
BMMC and BM eosinophils were obtained as previously described [41] [42] . BMMC from BALB/c and FVB mice (1×10 6 /ml) were sensitized overnight with Rat Myeloma IgE (1µg/ml; Molecular Probes, Invitrogen, Carlsbad, California. USA). Cells were washed, resuspended in Tyrode's buffer and pre-incubated in a 96-well plate (2×10 5 /well) with LXB 4 , LXA 4 or vehicle at the indicated concentrations for 30 min at 37°C. Cells were then activated by the addition of a goat anti-rat IgG (Fab)2' antibody (10µg/ml)(Jackson Immunoreserach Laboratories Inc, PA, USA) (30 min, 37°C) in Tyrode's buffer. Degranulation was evaluated by a colorimetric enzymatic β-hexosaminidase release assay 43 . For TNF-α release, supernatants were collected 18 hrs following BMMC activation for evaluation of mTNF-α quantified by ELISA (Peprotech Asia, Israel). For chemotaxis, BM eosinophils were similarly pre-treated and then seeded into the upper chamber of a 24 transwell plate (2×10 5 /well/100µl) (Corning) with a 5.0 µm pore size polycarbonate membrane. Cells were incubated (37°C, 3 hours) to allow migration across the membrane in response to medium only or medium with murine eotaxin (R&D biosystems, Minneapolis, Minnesota, USA) in the lower wells (50ng/ml/600µl). Migrated BM eosinophils were assessed by aspirating a fixed volume from the lower wells and counting the cells by flow cytometer (20 seconds, duplicate determinations).
Cytospin preparation
Nasal mucosa and BALF cells were resuspended in PBS/2% BSA, enumerated by a hemacytometer and cytocentrifuged (1000 rpm, 4 mins, r.t.) followed by staining with Modified Wright-Giemsa (Sigma Aldrich, Rehovot, Israel). Total cells, MC and eosinophils numbers were counted.
Evaluation of serum cytokines/chemokines and OVA specific IgE-levels
Blood samples were collected from the inferior vena cava and sera were stored (− 80°C) until measurement of OVA-specific IgE levels by ELISA (USCN life, China) and select cytokines/chemokines with Quantibody® Mouse cytokine array 1 (Ray Biotech, Inc. Norcross, Georgia, USA).
BALF and Lung sample preparation and evaluation
Bronchoalveolar lavage (BAL) was performed with 2 × 1 ml aliquots of PBS with 0.6 mM EDTA. Lungs were fixed at 25cm H 2 O in 10% buffered formalin and paraffin embedded for hematoxylin and eosin (H&E) and Periodic Acid Schiff (PAS) staining (Sigma). Cell-free BALF (centrifuged at 2000g for 10 min) were coded and select cytokines/chemokines measured by bead array (Pierce Biotechnology, Inc., Rockford, Illinois, USA). 
RNA isolation and Real Time PCR
Statistical analysis
All parameters were analyzed using GraphPad Prism 5 software (GraphPad Software, La Jolla, California). Data are expressed as means ±SEMs. Statistical comparisons were performed using 1-way ANOVA, followed by the Tukey post test. When only 2 groups were compared statistical differences were determined using the unpaired Student t-test. A p value of less than 0.05 was considered significant. 
